(Source: Abeona Therapeutics Inc) NEW YORK, NY and CLEVELAND, OH -- (Marketwired) -- 05/17/16 -- Abeona Therapeutics Inc.(NASDAQ: ABEO), a clinical-stage biopharmaceutical company focused on developing products for severe and life-threatening rare genetic diseases, announced today that the first patient in a Phase 1/2 trial for ABO-102 (AAV-SGSH), a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A (a.k.a Mucopolysaccharidosis Type IIIA or MPS IIIA) has been enrolled at Nationwide Children's Hospital (Columbus, Ohio). 'MPS IIIA is a profound and deadly lysosomal storage disease with no approved treatments available. Caused by a single gene defect, most of...
↧